A Multicenter Evaluation of the US Prevalence and Regional Variation in Macrolide-Resistant S. pneumoniae in Ambulatory and Hospitalized Adult Patients in the United States-Reference-Cited by-同舟云学术

A Multicenter Evaluation of the US Prevalence and Regional Variation in Macrolide-Resistant S. pneumoniae in Ambulatory and Hospitalized Adult Patients in the United States

Published:2021-02-04 Issue:7 Volume:8 Page:
ISSN:2328-8957
Container-title:Open Forum Infectious Diseases
language:en
Short-container-title:

Author:

Gupta Vikas¹,Yu Kalvin C¹,Schranz Jennifer²,Gelone Steven P²

Affiliation:

1. Becton, Dickinson and Company, Franklin Lakes, New Jersey, USA

2. Nabriva Therapeutics US, Inc., King of Prussia, Pennsylvania, USA

Abstract

Abstract Macrolide resistance was found in 39.5% of 3626 nonduplicate Streptococcus pneumoniae isolates from adult ambulatory and inpatient settings at 329 US hospitals (2018–2019). Macrolide resistance was significantly higher for respiratory vs blood isolates and ambulatory vs inpatient settings. Despite geographic variation, S. pneumoniae macrolide resistance was >25% in most regions.

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Oncology

Link

http://academic.oup.com/ofid/advance-article-pdf/doi/10.1093/ofid/ofab063/36196427/ofab063.pdf

Reference36 articles.

1. Streptococcus pneumoniae’s virulence and host immunity: aging, diagnostics, and prevention;Brooks;Front Immunol,2018

2. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infection in 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016;GBD 2016 Lower Respiratory Infections Collaborators;Lancet Infect Dis,2018

3. U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination;Griffin;N Engl J Med,2013

4. Impact of existing vaccines in reducing antibiotic resistance: primary and secondary effects;Klugman;Proc Natl Acad Sci U S A,2018

5. Oral lefamulin vs moxifloxacin for early clinical response among adults with community-acquired bacterial pneumonia. The LEAP 2 randomized clinical trial;Alexander;JAMA,2019

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antimicrobial Prescription Patterns for Acute Sinusitis 2015–2022: A Comparison to Published Guidelines;American Journal of Rhinology & Allergy;2024-09-12

2. Clinical and economic burden of invasive pneumococcal disease and noninvasive all-cause pneumonia in hospitalized US adults: A multicenter analysis from 2015 to 2020;International Journal of Infectious Diseases;2024-06

3. Utilization of broad‐ versus narrow‐spectrum antibiotics for the treatment of outpatient community‐acquired pneumonia among adults in the United States;Pharmacoepidemiology and Drug Safety;2024-03-21

4. Association Between Social Vulnerability and Streptococcus pneumoniae Antimicrobial Resistance in US Adults;Clinical Infectious Diseases;2024-03-14

5. Antimicrobial Resistance in Streptococcus pneumoniae before and after the Introduction of Pneumococcal Conjugate Vaccines in Brazil: A Systematic Review;Antibiotics;2024-01-09